Literature DB >> 7576956

The mycN/max protein complex in neuroblastoma. Short review.

A Wenzel1, M Schwab.   

Abstract

The oncogenic activation by amplification of the MYCN gene is frequently observed in human neuroblastomas and occasionally in other tumours with neuronal qualities. As a consequence of amplification, elevated levels of the mycN protein are expressed. mycN contains a C-terminal basic region (BR) that can bind to DNA, and a helix-loop-helix (HLH)-leucine zipper (Zip) domain, which is responsible for the physical interaction with another HLH-Zip protein, max. This principle structure is conserved among all members of the MYC gene family. The resulting dimers can bind to the DNA sequence CACGTG. The mycN protein, but not max, contains, near the N-terminus, a region conferring the ability to activate the transcription of genes. mycN/max heterodimers probably activate and max/max homodimers repress transcription of, as yet, unidentified target genes. In neuroblastoma cells, where mycN is deregulated, the balanced interaction of BR-HLH-Zip proteins is probably perturbed, and, therefore, genes controlled by mycN might be abnormally expressed and thereby alter normal cell growth with the consequence of tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7576956     DOI: 10.1016/0959-8049(95)00060-v

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

Review 1.  Patterns of oncogene activation in human neuroblastoma cells.

Authors:  R Corvi; L Savelyeva; M Schwab
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  N-myc amplification and its relationship to experimental therapy.

Authors:  A Livingstone; R J Mairs
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Prognostic significance of the proliferative activity in neuroblastoma.

Authors:  P Rudolph; T Lappe; B Hero; F Berthold; R Parwaresch; D Harms; D Schmidt
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

4.  MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.

Authors:  Etienne Blanc; David Goldschneider; Eric Ferrandis; Michel Barrois; Gwenaëlle Le Roux; Stéphane Leonce; Sétha Douc-Rasy; Jean Bénard; Gilda Raguénez
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

Review 5.  Neuroblastoma treatment in the post-genomic era.

Authors:  Maria Rosaria Esposito; Sanja Aveic; Anke Seydel; Gian Paolo Tonini
Journal:  J Biomed Sci       Date:  2017-02-08       Impact factor: 8.410

Review 6.  Molecular targeting therapies for neuroblastoma: Progress and challenges.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2020-11-06       Impact factor: 12.944

Review 7.  Personalized Medicine for Neuroblastoma: Moving from Static Genotypes to Dynamic Simulations of Drug Response.

Authors:  Jeremy Z R Han; Jordan F Hastings; Monica Phimmachanh; Dirk Fey; Walter Kolch; David R Croucher
Journal:  J Pers Med       Date:  2021-05-11

8.  Cytotoxic activity of nemorosone in neuroblastoma cells.

Authors:  D Díaz-Carballo; S Malak; W Bardenheuer; M Freistuehler; H P Reusch
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

Review 9.  Cell death-based treatment of neuroblastoma.

Authors:  Kadri Valter; Boris Zhivotovsky; Vladimir Gogvadze
Journal:  Cell Death Dis       Date:  2018-01-25       Impact factor: 8.469

10.  Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma.

Authors:  Timothy R Gershon; Andrew J Crowther; Andrey Tikunov; Idoia Garcia; Ryan Annis; Hong Yuan; C Ryan Miller; Jeffrey Macdonald; James Olson; Mohanish Deshmukh
Journal:  Cancer Metab       Date:  2013-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.